Clinical TrialsSearch results
Number of results: 932
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Other
- A Phase 3 Study of TAS-120 (Futibatinib) in Patients with intrahepatic Cholangiocarcinoma
- Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
- Zhang Yan
- 2020-11-09
Other
- A Phase 3 trial of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab in participants who are cisplatin-ineligible or decline cisplatin with Muscle-Invasive Bladder Cancer
- Muscle-invasive Bladder Cancer
- Fujita Tomoko
- 2023-03-03
Recruiting
- A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD
- Atopic Dermatitis
- Jain Neal
- 2023-07-01
Recruiting
- A Phase 3, Open-label Study Assessing Self-administered Rocatinlimab (AMG 451) in Subjects With Moderate-to-severe AD
- Atopic Dermatitis
- Chen Sarah
- 2024-04-23
Other
- A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD
- Atopic Dermatitis
- Schwartz-Sagi Liat
- 2023-04-03
Recruiting
- A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in warm autoimmune hemolytic anemia (wAIHA) patients who failed at least one line of treatment.
- Warm Autoimmune Hemolytic Anemia
- Yamauchi Kyosuke
- 2023-02-01
Other
- A phase I study of vinorelbine concurrent with thoracic radiotherapy in elderly patients with l locally advanced non-small cell lung cancer(WJTOG 3005).
- Non-small cell lung cancer
- West Japan Oncology Group
- 2008-09-26
Other
- A phase I trial of combination chemotherapy with docetaxel and 5-fluorouracil (DF) for advanced esophagogastric carcinoma (KDOG 0902 P1)
- advanced or recurrent esophagogastric carcinoma
- Kitasato University School of Medicine
- 2009-06-03
Other
- A Phase I/II study of JR-031 for the patients of standard primary treatment-refractory acute graft-versus-host disease (acute GVHD) after hematopoietic stem cell transplantation
- Standard primary treatment-refractory acute GVHD
- JCR pharmaceuticals Co.,Ltd
- 2009-02-19
Recruiting
- A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors (eNRGy)
- NSCLC, pancreatic adenocarcinoma and all other solid tumors with NRG1 fusion
- Wasserman Ernesto
- 2021-12-14